Table 1 Clinicopathological characteristics.

Age; median (range)

63 (44–73)

62 (49–77)

59 (41–73)

62 (34–72)

Gender (n (%))

 Male

15 (54%)

21 (66%)

8 (80%)

12 (67%)

 Female

13 (46%)

11 (34%)

2 (20%)

6 (33%)

Tumor location

 iCCA

17 (61%)

19 (59%)

6 (60%)

10 (56%)

 eCCA

11 (39%)

13 (41%)

4 (40%)

8 (44%)

Tumor morphology

 MF/PI

14 (50%)

12 (38%)

5 (50%)

9 (50%)

 ID/mixed type

14 (50%)

20 (62%)

5

9 (50%)

Surgical margin (R)

 R0

15 (54%)

21 (66%)

4 (40%)

11 (61%)

 R1

13 (46%)

11 (34%)

6 (60%)

7 (39%)

Histological type

 Well

20 (71%)

26 (81%)

8 (80%)

14 (78%)

 Moderately/poorly

8 (29%)

6 (19%)

2 (20%)

4 (22%)

Lymph node metastasis (N)

 N0

9 (32%)

21 (66%)

8 (80%)

12 (67%)

 N1

19 (68%)

11 (34%)

2 (20%)

6 (33%)

TNM^$ staging

 I-II

5 (18%)

10 (31%)

2 (20%)

5 (28%)

 III-IV

23 (82%)

22 (69%)

8 (80%)

13 (72%)

Preoperative laboratory data^$

 Cholesterol (mg/dL)

174.5 (135–290)

180 (93–266)

197 (103–251)

190.5 (107–257)

 Albumin (g/dL)

4.2 (2.9–4.8)

4.2 (2.9–5.3)

3.7 (2.6–4.4)

4.3 (2.8–4.7)

 Globulin (g/dL)

3.6 (2.5–4.8)

3.3 (1.7–4.8)

3.3 (2.6–5.1)

3.1 (2.5–4.9)

 Total protein (g/dL)

7.8 (5.4–8.3)

7.6 (4.6–8.8)

7.1 (6.6–7.7)

7.5 (5.4–9.4)

 Direct bilirubin (mg/dL)

0.2 (0.1–1.3)

0.2 (0.1-1)

1.4 (0.2–5.1)

0.3 (0.1–2.9)

 Total bilirubin (mg/dL)

0.4 (0.2–1.8)

0.5 (0.3–5.2)

1.9 (0.5–6.2)

0.5 (0.3–3.1)

 AST (U/L)

29 (10–57)

29 (17–193)

56 (25–95)

44 (18–195)

 ALT (U/L)

25 (10–99)

31 (2–88)

51 (30–78)

31 (17–228)

 ALP (U/L)

177.5 (65-1068)

125 (61–716)

264.5 (92–899)

133.5 (67–397)

Tumor biomarkers^$

 CA19-9 (ng/mL)

279.4 (0.6–1000)

112.2 (0.8–1000)

275.8 (1.5–1000)

195 (1.07–1000)

 CEA (U/mL)

9.72 (1.03–1000)

7.2 (1.1-109.1)

8.8 (2.6-128.5)

7.3 (1.94–402)